# Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis

> **NCT00396409** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 128 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** Depigoid
- **DRUG:** Omalizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00396409
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396409, "Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00396409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*